HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chr. Hansen Flags Challenging Outlook For Probiotic Supplements Market

Executive Summary

The global probiotic supplements industry is facing a "very challenging time" given the worsening macroeconomic situation, according to Danish ingredients supplier Chr. Hansen.

You may also be interested in...



Euro Q2 Consumer Health Earnings Preview: Volatility, Delay, Upturn And Goodbye

Major Europe-based consumer health players Bayer, Sanofi, Reckitt and GSK feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2022 results over the coming weeks.

Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold

Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.

P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar

Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel